Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,725 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07175077 | 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI) | recruiting | — | 20 | University of Missouri-ColumbiaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05178693 | Lutathera and ASTX727 in Neuroendocrine Tumours(LANTana) | recruiting | Phase 1 | 27 | Imperial College LondonOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07244016 | Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC(ES-SCLC) | recruiting | — | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07245446 | A Study of Ivonescimab in First-Line ES-SCLC | recruiting | Phase 2 | 180 | AkesoINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246304 | TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC | recruiting | Early Phase 1 | 24 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05588388 | Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases(BELIEVE) | recruiting | Phase 2 | 39 | Kamya SankarOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06283719 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 265 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05024929 | Targeted Therapy to Increase RAI Uptake in Metastatic DTC | recruiting | — | 32 | Children's Hospital of PhiladelphiaOTHER | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06062745 | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | recruiting | Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 1 | 22 | Emory UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05265429 | Biology of Young Lung Cancer Study: The YOUNG LUNG Study | recruiting | — | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT03160274 | Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions | recruiting | — | 2,000 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT06940440 | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | recruiting | Phase 1 | 9 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT07085572 | Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer(INTERVAL) | recruiting | Phase 2 | 31 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT04325425 | Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary(FOLFIRINEC) | recruiting | Phase 2 | 218 | Centre Hospitalier Universitaire DijonOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07195500 | Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma | recruiting | — | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06838208 | Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | recruiting | Phase 2 | 56 | Anhui Provincial Cancer HospitalOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07045935 | Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment(ProBOLIC) | recruiting | Phase 4 | 60 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188441 | Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. | recruiting | Phase 2 | 40 | Chengcheng GuoOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06256705 | Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort(OPERANDI-NET) | recruiting | N/A | 80 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06536257 | Personalised Immunotherapy Platform(PIP-PREDICT) | recruiting | — | 1,000 | Melanoma Institute AustraliaOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06021483 | Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection | recruiting | — | 300 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06831461 | Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors(PRIDE) | recruiting | N/A | 156 | Tata Memorial CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07161882 | ALG-LungCancerRegistry (SAFRO2202)(SAFRO2202) | recruiting | — | 3,750 | Société Algérienne de Formation et de Recherche en OncologieOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05387603 | Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.(START-NET) | recruiting | Phase 3 | 300 | Lund University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05874401 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | recruiting | Phase 4 | 302 | Pharmacosmos A/SINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06529081 | Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer | recruiting | N/A | 165 | Copernicus Memorial HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06908629 | Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors | recruiting | N/A | 120 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT06359847 | Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 60 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07138716 | Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC | recruiting | N/A | 30 | Luo YapingOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06258642 | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | recruiting | N/A | 39 | Fudan UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07121998 | Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms(PROGRESS-TMZ) | recruiting | — | 94 | Uppsala UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06813742 | 18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma | recruiting | — | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07109401 | Perioperative Immunotherapy for Resectable Limited-Stage SCLC | recruiting | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06541652 | A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers(FFCD-2205) | recruiting | — | 150 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT04268121 | Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas(NEONEC) | recruiting | Phase 2 | 78 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04837885 | Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases(LUTARTERIAL) | recruiting | Phase 2 | 23 | University Hospital, BordeauxOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06395402 | 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry(LUMOD-ID) | recruiting | Phase 2 | 120 | University of IowaOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07070011 | Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer | recruiting | — | 38 | Shanghai Chest Hospital of Shanghai Jiao Tong UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05173246 | JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 3, 2025source: clinicaltrials